259 related articles for article (PubMed ID: 24635741)
1. Research on drug safety and effectiveness using pharmacoepidemiological databases.
Andersen M
J Intern Med; 2014 Jun; 275(6):548-50. PubMed ID: 24635741
[No Abstract] [Full Text] [Related]
2. Use of health care databases in pharmacoepidemiology.
Hennessy S
Basic Clin Pharmacol Toxicol; 2006 Mar; 98(3):311-3. PubMed ID: 16611207
[TBL] [Abstract][Full Text] [Related]
3. Healthcare databases in Europe for studying medicine use and safety during pregnancy.
Charlton RA; Neville AJ; Jordan S; Pierini A; Damase-Michel C; Klungsøyr K; Andersen AM; Hansen AV; Gini R; Bos JH; Puccini A; Hurault-Delarue C; Brooks CJ; de Jong-van den Berg LT; de Vries CS
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):586-94. PubMed ID: 24664855
[TBL] [Abstract][Full Text] [Related]
4. The growing role of epidemiology in drug safety regulation.
Hamburg MA
Epidemiology; 2011 Sep; 22(5):622-4. PubMed ID: 21811108
[No Abstract] [Full Text] [Related]
5. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
6. Pediatric post-marketing safety systems in North America: assessment of the current status.
McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B vaccination and multiple sclerosis: a data mining perspective.
Hauben M; Sakaguchi M; Patadia V; M Gerrits C
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):943-5. PubMed ID: 17636551
[No Abstract] [Full Text] [Related]
8. What is pharmacoepidemiology? Definition, methods, interest and clinical applications.
Montastruc JL; Benevent J; Montastruc F; Bagheri H; Despas F; Lapeyre-Mestre M; Sommet A
Therapie; 2019 Apr; 74(2):169-174. PubMed ID: 30389102
[TBL] [Abstract][Full Text] [Related]
9. What can we really learn from observational studies?: the need for empirical assessment of methodology for active drug safety surveillance and comparative effectiveness research.
Madigan D; Ryan P
Epidemiology; 2011 Sep; 22(5):629-31. PubMed ID: 21811110
[No Abstract] [Full Text] [Related]
10. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
11. Response to comment on 'empirical assessment of methods for risk identification in healthcare data'.
Ryan PB; Madigan D; Stang PE; Marc Overhage J; Racoosin JA; Hartzema AG
Stat Med; 2013 Mar; 32(6):1075-7. PubMed ID: 23413215
[No Abstract] [Full Text] [Related]
12. Drug safety data mining with a tree-based scan statistic.
Kulldorff M; Dashevsky I; Avery TR; Chan AK; Davis RL; Graham D; Platt R; Andrade SE; Boudreau D; Gunter MJ; Herrinton LJ; Pawloski PA; Raebel MA; Roblin D; Brown JS
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):517-23. PubMed ID: 23512870
[TBL] [Abstract][Full Text] [Related]
13. Comment on 'empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership'.
Gagne JJ; Schneeweiss S
Stat Med; 2013 Mar; 32(6):1073-4. PubMed ID: 23413214
[No Abstract] [Full Text] [Related]
14. Estimating national drug consumption using data at different points in the pharmaceutical supply chain.
Cook MN
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):754-7. PubMed ID: 16989003
[No Abstract] [Full Text] [Related]
15. Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.
Ryan PB; Madigan D; Stang PE; Overhage JM; Racoosin JA; Hartzema AG
Stat Med; 2012 Dec; 31(30):4401-15. PubMed ID: 23015364
[TBL] [Abstract][Full Text] [Related]
16. Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safety.
Duszynski KM; Stark JH; Cohet C; Huang WT; Shin JY; Lai EC; Man KKC; Choi NK; Khromava A; Kimura T; Huang K; Watcharathanakij S; Kochhar S; Chen RT; Pratt NL
Pharmacoepidemiol Drug Saf; 2021 Jul; 30(7):843-857. PubMed ID: 33634545
[TBL] [Abstract][Full Text] [Related]
17. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
[TBL] [Abstract][Full Text] [Related]
18. Statistical visualization for assessing performance of methods for safety surveillance using electronic databases.
Li X; Hui S; Ryan P; Rosenman M; Overhage M
Pharmacoepidemiol Drug Saf; 2013 May; 22(5):503-9. PubMed ID: 23408560
[TBL] [Abstract][Full Text] [Related]
19. Drug-safety pilot makes the grade.
Ledford H
Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
[No Abstract] [Full Text] [Related]
20. [Proposal of guidelines for the set-up of pharmaco-epidemiologic studies in drug surveillance].
de Tricornot B; Saddier P; Bons B; Clément JP; Courtand M; Lamarque V; Thomas A; Tomczyk S; Vaissère J
Therapie; 1997; 52(6):579-85. PubMed ID: 9734111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
